Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Int J Mol Sci. 2023 Apr 13;24(8):7205. doi: 10.3390/ijms24087205.
Parkinson's disease (PD) is a multifactorial disorder involving both motor and non-motor symptoms caused by the progressive death of distinct neuronal populations, including dopaminergic neurons in the substantia nigra. The deposition of aggregated α-synuclein protein into Lewy body inclusions is a hallmark of the disorder, and α-synuclein pathology has been found in the enteric nervous system (ENS) of PD patients up to two decades prior to diagnosis. In combination with the high occurrence of gastrointestinal dysfunction in early stages of PD, current evidence strongly suggests that some forms of PD may originate in the gut. In this review, we discuss human studies that support ENS Lewy pathology as a characteristic feature of PD, and present evidence from humans and animal model systems that α-synuclein aggregation may follow a prion-like spreading cascade from enteric neurons, through the vagal nerve, and into the brain. Given the accessibility of the human gut to pharmacologic and dietary interventions, therapeutic strategies aimed at reducing pathological α-synuclein in the gastrointestinal tract hold significant promise for PD treatment.
帕金森病(PD)是一种多因素疾病,涉及运动和非运动症状,由包括黑质多巴胺能神经元在内的不同神经元群体的进行性死亡引起。聚集的α-突触核蛋白沉积成路易体包涵物是该疾病的标志,并且在 PD 患者的肠神经系统(ENS)中已经发现了α-突触核蛋白病理学,早在诊断前二十年就已经发现了。结合 PD 早期胃肠道功能障碍的高发生率,目前的证据强烈表明,某些形式的 PD 可能起源于肠道。在这篇综述中,我们讨论了支持 ENS 路易体病理学作为 PD 特征的人体研究,并提出了来自人类和动物模型系统的证据,表明α-突触核蛋白聚集可能遵循一种类朊病毒样扩散级联,从肠神经元通过迷走神经进入大脑。鉴于人类肠道对药物和饮食干预的可及性,旨在减少胃肠道中病理性α-突触核蛋白的治疗策略为 PD 治疗提供了重要的前景。